USA TODAY - Bristol’s $499M drug–pricing settlement among biggest
Drugmaker Bristol-Myers Squibb said Thursday that it would pay $499 million to settle federal investigations into its pricing, sales and marketing practices. The tentative agreement is one of the biggest in recent years for drugmakers regarding drug marketing and pricing. It aims to settle investigations into Bristol’s marketing of schizophrenia and bipolar disorder drug Abilify for conditions the drug was not approved to treat, says Bristol spokesman Jeff Macdonald.
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
Business Plan Sample
It also covers some cases in which Bristol allegedly inflated drug prices so government programs for the poor and elderly paid more. It would not negate other so-called average wholesale price cases launched against Bristol by several states and others, Bristol said. No criminal charges would be filed against Bristol. The agreement is subject to approval by the U.S. Department of Justice and was struck with Justice and the U.S. Attorney for the District of Massachusetts. Their investigation covered more than …
Read the full article with a Free Trial at MyWire.
